Ascentage Pharma developed olverembatinib (HQP1351), novel drug candidate, for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST) who had obtained first-line treatment.
Olverembatinib, is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with TKI-resistant chronic-phase chronic myeloid leukaemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation.
Olverembatinib, is the primary and most effective third-technology BCR-ABL inhibitor authorised in China for the treatment of patients TKI-resistant continual-segment continual myeloid leukaemia (CML-CP) or accelerated-segment CML (CML-AP) harbouring the T315I mutation.
While being clinically evolved and followed for the treatment of haematologic malignancies, olverembatinib additionally possed powerful antitumor response against GIST in preclinical and early medical studies, along with mainly promising efficacy in individuals with SDH-poor GIST.
Results from an ongoing Phase Ib/II study confirmed an excellent scientific gain rate (CBR) of 93.8 percent in sufferers with this subtype of GIST.
GIST is a form of malignancy that arises in mesenchymal tissues of the gastrointestinal tract, and maximum patients with GIST harbor KIT or PDGFRA mutations. The advent of TKIs has extensively stepped forward the diagnosis of these patients. However, patients with SHD-poor GIST, a unprecedented subtype of GIST, nonetheless have extensive unmet clinical needs. Currently, there is no standard of care for patients with relapsed or advanced SDH-deficient GIST.
